Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Enterocolitis - Overview
Enterocolitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Enterocolitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Enterocolitis - Companies Involved in Therapeutics Development
Avexegen Therapeutics Inc
Glycohub Inc
Glycosyn LLC
Infant Bacterial Therapeutics AB
Leadiant Biosciences Inc
Limil BioSciences Inc
Noveome Biotherapeutics Inc
Plakous Therapeutics Inc
Scioto Biosciences Inc
Synthetic Biologics Inc
Worphmed Srl
Enterocolitis - Drug Profiles
alpha-1 proteise inhibitor (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-34 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IBP-9414 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
melatonin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NRG-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PROTEGO-PD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SB-121 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Infectious Diarrhea and Necrotizing Enterocolitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Necrotizing Enterocolitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-266 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STP-206 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SYN-020 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Enterocolitis - Dormant Projects
Enterocolitis - Product Development Milestones
Featured News & Press Releases
Jul 05, 2019: Infant Bacterial enrols first patient in NEC study
May 19, 2019: FDA and Infant Bacterial Therapeutics agree on the design of Phase III study
Mar 05, 2019: Infant Bacterial Therapeutics announces first distribution agreement
Nov 21, 2018: The Phase 3 study protocol is modified after IBT’s meeting with the FDA
Nov 09, 2018: IBTs Chief Scientific Officer invited to speak at NEC Society Symposium 2019
May 15, 2018: Infant Bacterial Therapeutics: Interim Magement Statement, January 1 - March 31, 2018
Mar 05, 2018: Prometic receives Rare Pediatric Disease Desigtion from U.S. FDA for its Inter-Alpha-Inhibitor-Proteins
Feb 15, 2018: Prometic granted orphan drug desigtion by FDA for Inter-Alpha-Inhibitor-Proteins for treatment of necrotizing enterocolitis (NEC)
Dec 11, 2017: Infant Bacterial Therapeutics presents data from its Safety and Tolerability Study in premature infants
Nov 23, 2017: Infant Bacterial Therapeutics Interim Magement Statement, January 1 - September 29, 2017
Sep 28, 2017: European Medicines Agency adopts a positive opinion on the Paediatric Investigation Plan for IBT’s lead product
Sep 11, 2017: Infant Bacterial Therapeutics announces that top line data demonstrate similar safety and tolerability profile in the active and placebo groups
Jan 24, 2017: Last patient enrolled in IBT’s Phase 2 study
Nov 21, 2016: Positive recommendation from the independent Data Safety Monitoring Board to continue Phase II Study
Jun 07, 2016: Infant Bacterial Therapeutics enrolls First Patient in Phase 2 Clinical Trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Enterocolitis, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development for Enterocolitis, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Enterocolitis - Pipeline by Avexegen Therapeutics Inc, H2 2019
Enterocolitis - Pipeline by Glycohub Inc, H2 2019
Enterocolitis - Pipeline by Glycosyn LLC, H2 2019
Enterocolitis - Pipeline by Infant Bacterial Therapeutics AB, H2 2019
Enterocolitis - Pipeline by Leadiant Biosciences Inc, H2 2019
Enterocolitis - Pipeline by Liminal BioSciences Inc, H2 2019
Enterocolitis - Pipeline by Noveome Biotherapeutics Inc, H2 2019
Enterocolitis - Pipeline by Plakous Therapeutics Inc, H2 2019
Enterocolitis - Pipeline by Scioto Biosciences Inc, H2 2019
Enterocolitis - Pipeline by Synthetic Biologics Inc, H2 2019
Enterocolitis - Pipeline by Worphmed Srl, H2 2019
Enterocolitis - Dormant Projects, H2 2019